New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - posaconazole 100mg - modified release tablet - 100 mg - active: posaconazole 100mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose hypromellose acetate succinate isopropyl alcohol magnesium stearate microcrystalline cellulose opadry brown 03b565138 opadry clear 03k19229 purified water   - indicated for use in the treatment of the following invasive fungal infections in patients 18 years of age or older: " invasive aspergillosis in patients with disease that is refractory to, or are intolerant of, amphotericin b, itraconazole or voriconazole. " esophageal candidiasis or candidemia in patients with disease that is refractory to, or who are intolerant of, amphotericin b, fluconazole or itraconazole. " fusariosis, zygomycosis, cryptococcosis, chromoblastomycosis, and mycetoma in patients with disease refractory to other therapy, or patients who are intolerant of other therapy. " coccidioidomycosis. indicated for use as: " prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients 13 years of age and older who are at high risk of developing these infections, such as patients with prolonged neutropenia or hematopoietic stem cell transplant (hsct) recipients.

Canada - English - Health Canada

merck canada inc - posaconazole - suspension - 200mg - posaconazole 200mg - azoles

Canada - English - Health Canada

merck canada inc - posaconazole - tablet (delayed-release) - 100mg - posaconazole 100mg - azoles

Canada - English - Health Canada

merck canada inc - posaconazole - solution - 300mg - posaconazole 300mg - azoles

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - posaconazole - oral suspension - 40mg/1ml

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - posaconazole - suspension - 40mg/ml - posaconazole 40mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - posaconazole -

European Union - English - EMA (European Medicines Agency)

intervet international bv - orbifloxacin, mometasone furoate, posaconazole - otologicals - dogs - treatment of acute otitis externa and acute exacerbations of recurrent otitis externa, associated with bacteria susceptible to orbifloxacin and fungi susceptible to posaconazole, in particular malassezia pachydermatis.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: propyl gallate; methacrylic acid - ethyl acrylate copolymer (1:1); xylitol; sodium stearylfumarate; triethyl citrate; microcrystalline cellulose; croscarmellose sodium; hyprolose; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - poscole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:,? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.,? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,poscole is also indicated for the prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.